Absence of EGFR mutation in the kinase domain in common human cancers besides non-small cell lung cancer

被引：75

作者：

Lee, JW ^{[1
]}

Soung, YH ^{[1
]}

Kim, SY ^{[1
]}

Park, WS ^{[1
]}

Nam, SW ^{[1
]}

Lee, JY ^{[1
]}

Yoo, NJ ^{[1
]}

Lee, SH ^{[1
]}

机构：

[1] Catholic Univ Korea, Coll Med, Dept Pathol, Seoul 137701, South Korea

来源：

INTERNATIONAL JOURNAL OF CANCER | 2005年 / 113卷 / 03期

关键词：

D O I：

10.1002/ijc.20591

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：510 / 511

页数：2

共 7 条

[1]

Ciardiello F, 2000, CLIN CANCER RES, V6, P2053

[2] Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer [J].

Fukuoka, M ;

Yano, S ;

Giaccone, G ;

Tamura, T ;

Nakagawa, K ;

Douillard, JY ;

Nishiwaki, Y ;

Vansteenkiste, J ;

Kudoh, S ;

Rischin, D ;

Eek, R ;

Horai, T ;

Noda, K ;

Takata, I ;

Smit, E ;

Averbuch, S ;

Macleod, A ;

Feyereislova, A ;

Dong, RP ;

Baselga, J .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (12) :2237-2246

[3] Epidermal growth factor receptor: mechanisms of activation and signalling [J].

Jorissen, RN ;

Walker, F ;

Pouliot, N ;

Garrett, TPJ ;

Ward, CW ;

Burgess, AW .

EXPERIMENTAL CELL RESEARCH, 2003, 284 (01) :31-53

[4] Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib [J].

Lynch, TJ ;

Bell, DW ;

Sordella, R ;

Gurubhagavatula, S ;

Okimoto, RA ;

Brannigan, BW ;

Harris, PL ;

Haserlat, SM ;

Supko, JG ;

Haluska, FG ;

Louis, DN ;

Christiani, DC ;

Settleman, J ;

Haber, DA .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (21) :2129-2139

[5] EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy [J].

Paez, JG ;

Jänne, PA ;

Lee, JC ;

Tracy, S ;

Greulich, H ;

Gabriel, S ;

Herman, P ;

Kaye, FJ ;

Lindeman, N ;

Boggon, TJ ;

Naoki, K ;

Sasaki, H ;

Fujii, Y ;

Eck, MJ ;

Sellers, WR ;

Johnson, BE ;

Meyerson, M .

SCIENCE, 2004, 304 (5676) :1497-1500

[6]

Wakeling AE, 2002, CANCER RES, V62, P5749

[7] ZD1839 ('Iressa'), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model [J].

Williams, KJ ;

Telfer, BA ;

Stratford, IJ ;

Wedge, SR .

BRITISH JOURNAL OF CANCER, 2002, 86 (07) :1157-1161

← 1 →